MZ
Distinguished in Parathyroid Cancer
Check Dr. Mark E. Zafereo's experience treating your condition:
About Dr. Mark E. Zafereo

Mark Zafereo is an Otolaryngologist in Houston, Texas. Zafereo has been practicing medicine for over 17 years and is rated as a Distinguished expert by MediFind in the treatment of Parathyroid Cancer. He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Thyroid Cancer, Anaplastic Thyroid Cancer, Papillary Thyroid Cancer, Medullary Thyroid Carcinoma, and Laryngectomy. He is licensed to treat patients in Texas. Zafereo is currently accepting new patients.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 3 clinical trials in the past 15 years. In particular, he has co-authored 20 articles in the study of Parathyroid Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Mark E. Zafereo it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Locations
1515 Holcombe Blvd Unit 1445, Md Anderson Cancer Center Dept Head And Neck Surgery, Houston, TX 77030
Background & Education
Graduate Institution
University Of Texas Medical School At Houston, 2005
Specialties
Otolaryngology
Licenses
Otolaryngology in TX
Hospital Affiliations
University Of Texas MD Anderson Cancer Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


3 Clinical Trials

Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer
Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Distinguished
Advanced
Advanced